55-06-1
55-06-1
Chemical Structure
Liothyronine sodium
Synonym(s): Triiodothyronine sodium; 3,3',5-Triiodo-L-thyronine sodium; T3 sodium
- CAS No.: 55-06-1
- Formula:C15H11I3NNaO4
- Molecular Weight:672.96
IUPAC Name: sodium (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoate
InChIKey: SBXXSUDPJJJJLC-YDALLXLXSA-M
SMILES: N[C@@H](CC1=CC(I)=C(C(I)=C1)OC2=CC=C(O)C(I)=C2)C(O[Na])=O
Biological Activity: Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Liothyronine sodium | 99.63% | Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Liothyronine sodium (Standard) | 98.70% | Liothyronine (sodium) (Standard) is the analytical standard of Liothyronine (sodium). This product is intended for research and analytical applications. Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94. [Content Brief]
- [2]. Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92. [Content Brief]
- [3]. Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 1;20(11):3622-34. [Content Brief]
